On July 11, 2025, Sonnet BioTherapeutics Holdings, Inc. entered into a Business Combination Agreement for a merger with Rorschach I LLC and Hyperliquid Strategies Inc, expected to close in the second half of 2025, with substantial investments including $200 million in HYPE Tokens and expected cash proceeds of $305 million.